(MENAFN- GetNews)

Netherton Syndrome is a rare disorder that is inherited as an autosomal recessive trait. The disorder is caused due to the mutation in the SPINK5 gene located on chromosome 5 which is responsible for encoding proteins that serve as the break on the activity of certain proteases in the skin protein. This disorder mainly affects the immune system, skin, and hair of an individual and is characterized by elevated IgE levels, scaling skin, hair anomalies, and increased susceptibility to atopic eczema. The syndrome is estimated to affect 1 in 200,000 newborn.

DelveInsight's,  'Netherton Syndrome Pipeline Insight, 2021,  report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Some of Netherton Syndrome Companies are:

• Novartis
• Timber pharmaceuticals
• Bridge Biopharma
• Evotec AG
• Dermelix Biotherapeutics
• Krystal Biotech
• And Many Others

Request for free Sample Report:

DelveInsight's Netherton Syndrome Report covers around 6+ products under different phases of clinical development like:

• Late stage products (Phase II/III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of Netherton Syndrome Therapies are:

• ·         LM 030
• Isotretinoin
• BBP-561
• And Many Others

Request for free Sample Report:

Current Netherton Syndrome Treatment Scenario and Netherton Syndrome Emerging Therapies :

• How many companies are developing Netherton Syndrome drugs?
• How many Netherton Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Netherton Syndrome?
• What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Netherton Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Netherton Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Request for free Sample Report:

Table of Contents:

Introduction

Executive Summary

Netherton Syndrome: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Netherton Syndrome DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Netherton Syndrome Collaboration Deals

Late Stage Products (Phase II/III)

• Comparative Analysis

LM030: Novartis

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Isotretinoin: Timber Pharmaceuticals

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

Drug Name: Company Name

Drug profiles in the detailed report…..

Inactive Products

Netherton Syndrome Key Companies

Netherton Syndrome Key Products

Netherton Syndrome- Unmet Needs

Netherton Syndrome- Market Drivers and Barriers

Netherton Syndrome- Future Perspectives and Conclusion

Netherton Syndrome Analyst Views

Netherton Syndrome Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website:

MENAFN21042021003238003268ID1101960787